The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis
Open accessAbstract
OBJECTIVE: To compare the survival rates of women with BRCA associated breast cancer who did and did not undergo mastectomy of the contralateral breast. DESIGN: Retrospective analysis. SETTING: 12 cancer genetics clinics. PARTICIPANTS: 390 women with a family history of stage I or II breast cancer who were carriers of BRCA1 and BRCA2 mutations and initially treated with unilateral or bilateral mastectomy. 181 patients had mastectomy of the contralateral breast. Patients were followed for up to 20 years from diagnosis. MAIN OUTCOME MEASURE: Death from breast cancer. RESULTS: 79 women died of breast cancer in the follow-up period (18 in the bilateral mastectomy group and 61 in the unilateral mastectomy group). The median follow-up time was 14.3 years (range 0.1-20.0 years). At 20 years the survival rate for women who had mastectomy of the contralateral breast was 88% (95% confidence interval 83% to 93%) and for those who did not was 66% (59% to 73%). In a multivariable analysis, controlling for age at diagnosis, year of diagnosis, treatment, and other prognostic features, contralateral mastectomy was associated with a 48% reduction in death from breast cancer (hazard ratio 0.52, 95% confidence interval 0.29 to 0.93; P=0.03). In a propensity score adjusted analysis of 79 matched pairs, the association was not significant (0.60, 0.34 to 1.06; P=0.08). Based on these results, we predict that of 100 women treated with contralateral mastectomy, 87 will be alive at 20 years compared with 66 of 100 women treated with unilateral mastectomy. CONCLUSIONS: This study suggests that women who are positive for BRCA mutations and who are treated for stage I or II breast cancer with bilateral mastectomy are less likely to die from breast cancer than women who are treated with unilateral mastectomy. Given the small number of events in this cohort, further research is required to confirm these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Self-citationAntoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Self-citationDomchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
Foulkes, W. D. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg050 · Cited by 970
Self-citationRe: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., Olopade, O. I., Eisen, A., Weber, B., McLennan, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.033 · Cited by 621
Self-citationByrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., Mierzwa, T., Szwiec, M., Wiśniowski, R., Siolek, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7019 · Cited by 516
Self-citationProphylactic mastectomy for the prevention of breast cancer
Lostumbo, L., Carbine, N. E., & Wallace, J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002748.pub3 · Cited by 400
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307
Self-citationClinical Outcomes of Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations
Rennert, G., Bisland-Naggan, S., Barnett-Griness, O., Bar-Joseph, N., Zhang, S., Rennert, H. S., & Narod, S. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070608 · Cited by 302
Self-citationPredictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Metcalfe, K., Gershman, S., Lynch, H. T., Ghadirian, P., Tung, N., Kim-Sing, C., Olopade, O. I., Domchek, S., McLennan, J., Eisen, A., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.120 · Cited by 232
Self-citationByrski, T., Dent, R., Blecharz, P., Foszczynska-Kloda, M., Gronwald, J., Huzarski, T., Cybulski, C., Marczyk, E., Chrzan, R., Eisen, A., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3231 · Cited by 210
Self-citationMetcalfe, K. A., Lubinski, J., Ghadirian, P., Lynch, H., Kim-Sing, C., Friedman, E., Foulkes, W. D., Domchek, S., Ainsworth, P., Isaacs, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6078 · Cited by 176
Self-citationGoodwin, P. J., Phillips, K.-A., West, D. W., Ennis, M., Hopper, J. L., John, E. M., O'Malley, F. P., Milne, R. L., Andrulis, I. L., Friedlander, M. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.0068 · Cited by 167
Effect of Genetic Cancer Risk Assessment on Surgical Decisions at Breast Cancer Diagnosis
Weitzel, J. N. (2003) · Archives of Surgery · doi:10.1001/archsurg.138.12.1323 · Cited by 150
Prophylactic mastectomy for the prevention of breast cancer
Lostumbo, L., Carbine, N. E., Wallace, J., Ezzo, J., & Dickersin, K. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002748.pub2 · Cited by 123
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?
Narod, S. A., Metcalfe, K. A., Lynch, H. T., Ghadirian, P., Robidoux, A., Tung, N., Gaughan, E. M., Kim‐Sing, C., Olopade, O. I., Foulkes, W. D., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2429-x · Cited by 32
Self-citationNarod, S. A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1479-1 · Cited by 31
Self-citationPredictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Abouharb, S., & Litton, J. K. (2012) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2012.03.011 · Cited by 13
Cited by
Couch, F. J., Hart, S. N., Sharma, P., Toland, A. E., Wang, X., Miron, P., Olson, J. E., Godwin, A. K., Pankratz, V. S., Olswold, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1414 · Cited by 672
Paluch-Shimon, S., Cardoso, F., Sessa, C., Balmana, J., Cardoso, M. J., Gilbert, F., & Senkus, E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw327 · Cited by 399
Tung, N. M., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., Dragun, A., Gelpi, J. B., Hofstatter, E. W., Isaacs, C. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00299 · Cited by 332
Self-citationRisk-reducing mastectomy for the prevention of primary breast cancer
Carbine, N. E., Lostumbo, L., Wallace, J., & Ko, H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002748.pub4 · Cited by 266
ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)
Paluch-Shimon, S., Cardoso, F., Partridge, A. H., Abulkhair, O., Azim, H. A., Bianchi-Micheli, G., Cardoso, M.-J., Curigliano, G., Gelmon, K. A., Harbeck, N., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.284 · Cited by 254
Metadata
- Authors
- Metcalfe, K., Gershman, S., Ghadirian, P., Lynch, H. T., Snyder, C., Tung, N., Kim-Sing, C., Eisen, A., Foulkes, W. D., Rosen, B., Sun, P., & Narod, S. A.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2014-02-11
- Volume
- 348
- Issue
- feb11 9
- Pages
- g226-g226
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2045723104
- Cited by
- 305
- References
- 20
- FWCI
- 21.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.